| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Bal Pharma Limited (NSE: BALPHARMA)
BALPHARMA Technical Analysis
1.5
| As on 26th Apr 2024 BALPHARMA SHARE Price closed @ 100.30 and we RECOMMEND Buy for LONG-TERM with Stoploss of 99.82 & Sell for SHORT-TERM with Stoploss of 106.21 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BALPHARMASHARE Price
| Open | 98.40 | Change | Price | % |
| High | 100.65 | 1 Day | 2.00 | 2.03 |
| Low | 98.40 | 1 Week | 2.60 | 2.66 |
| Close | 100.30 | 1 Month | 1.45 | 1.47 |
| Volume | 8988 | 1 Year | 21.65 | 27.53 |
| 52 Week High 128.30 | 52 Week Low 64.45 | ||||
NSE INDIA Most Active Stocks
| IDEA | 14.00 | 0.72% |
| YESBANK | 26.15 | 0.77% |
| IRFC | 158.05 | 5.19% |
| GMRINFRA | 90.75 | 6.58% |
| HUDCO | 228.10 | 12.34% |
| MAHABANK | 67.65 | 3.68% |
| SAIL | 168.55 | 2.18% |
| NHPC | 92.55 | 1.65% |
| TATASTEEL | 165.80 | -1.13% |
| IDFCFIRSTB | 84.80 | 1.68% |
NSE INDIA Top Gainers Stocks
| ROSSELLIND | 468.35 | 20.00% |
| MGEL | 23.25 | 19.85% |
| KIRLOSIND | 5232.65 | 12.84% |
| HUDCO | 228.10 | 12.34% |
| DPABHUSHAN | 1133.45 | 10.42% |
| KECL | 130.60 | 10.30% |
| EXCEL | 0.55 | 10.00% |
| ACL | 98.15 | 9.79% |
| ACL | 98.15 | 9.79% |
| ACL | 98.15 | 9.79% |
NSE INDIA Top Losers Stocks
| LTTS | 4778.10 | -7.81% |
| BAJFINANCE | 6731.20 | -7.73% |
| DBSTOCKBRO | 50.90 | -5.91% |
| COMPUSOFT | 33.95 | -5.56% |
| KSB | 4674.75 | -5.21% |
| KSB | 4674.75 | -5.21% |
| KSB | 4674.75 | -5.21% |
| KSB | 4674.75 | -5.21% |
| KSB | 4674.75 | -5.21% |
| KSB | 4674.75 | -5.21% |
| BALPHARMA Daily Charts |
BALPHARMA Intraday Charts |
Whats New @ Bazaartrend |
BALPHARMA Free Analysis |
|
|
BALPHARMA Important Levels Intraday
| RESISTANCE | 104.64 |
| RESISTANCE | 103.25 |
| RESISTANCE | 102.39 |
| RESISTANCE | 101.53 |
| SUPPORT | 99.07 |
| SUPPORT | 98.21 |
| SUPPORT | 97.35 |
| SUPPORT | 95.96 |
BALPHARMA Target April 2024
| 4th UP Target | 159.57 |
| 3rd UP Target | 144.46 |
| 2nd UP Target | 135.12 |
| 1st UP Target | 125.78 |
| 1st DOWN Target | 99.12 |
| 2nd DOWN Target | 89.78 |
| 3rd DOWN Target | 80.44 |
| 4th DOWN Target | 65.33 |
BALPHARMA Weekly Target
| 4th UP Target | 116.39 |
| 3rd UP Target | 110.40 |
| 2nd UP Target | 106.69 |
| 1st UP Target | 102.99 |
| 1st DOWN Target | 92.41 |
| 2nd DOWN Target | 88.71 |
| 3rd DOWN Target | 85.00 |
| 4th DOWN Target | 79.01 |
BALPHARMA Target2024
| 4th UP Target | 206.04 |
| 3rd UP Target | 172.05 |
| 2nd UP Target | 151.04 |
| 1st UP Target | 130.03 |
| 1st DOWN Target | 70.08 |
| 2nd DOWN Target | 49.07 |
| 3rd DOWN Target | 28.06 |
| 4th DOWN Target | -5.93 |
Bal Pharma Limited ( NSE INDIA Symbol : BALPHARMA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BALPHARMA Synopsis Technicals View
| 50 Day EMA |
Close is Above EMA 50 (Short Term) |
Bullish | |
| 100 Day EMA | Close is Above EMA 100 (Mid Term) | Bullish | |
| 200 Day EMA | Close is Above EMA 200 (Long Term) | Bullish | |
| MACD (12 26 9) | MACD Line is Less Then SIGNAL Line | Bearish | |
| RSI (14) | RSI is Below 30 | Over Sold | |
| MFI (14) | MFI is 37.76 | Sideways | |
| CCI (20) | CCI is Below -100 | Over Sold | |
| WILLIAM %R (14) | William %R is Below -80 | Over Sold | |
| ADX (14) | ADX is Above 20 & +DI is Below -DI | Down Trend | |
| PSAR | Stoploss For Long Buy | 38.54 | |
| 10 Day Avg Volume | Traded -30.19 % Less then 10 Day Average Volume | ||
BALPHARMA Other Details
| Segment | EQ | |
| Market Capital | 1485319936.00 | |
| Sector | Healthcare | |
| Industry | Drug Manufacturers-Specialty & Generic | |
| Offical website | > | |
BALPHARMA Address
 |
||
BALPHARMA Latest News
BALPHARMA Business Profile
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India. Address: Lakshmi Narayan Complex, Bengaluru, India, 560052
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service